+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
3BBLACKBIO

3B BlackBio Dx Share Price

 

 

3B BlackBio Dx live price: ₹1200.1. It opened at ₹1,218 vs previous close ₹1,196; intraday high/low: ₹1,225/₹1,160. The 50 & 200 DMA stand at ₹1,246.68/₹1,362.04.

3B BlackBio Dx Performance

  • Today's Low
  • ₹1,160
  • Today's High
  • ₹1,225
  • 52 Week Low
  • ₹1,085
  • 52 Week High
  • ₹1,442
  • Open Price₹1,218
  • Previous Close₹1,196
  • Volume25,002
  • 50 DMA₹1,246.68
  • 100 DMA₹1,296.95
  • 200 DMA₹1,362.04

3B BlackBio Dx Chart

Investment Returns

  • Over 1 Month -0.22%
  • Over 3 Month -7.4%
  • Over 6 Month -10.96%
  • Over 1 Year -18.51%

Smart Investing Starts Here Start SIP with 3B BlackBio Dx for Steady Growth!

Invest Now

3B BlackBio Dx Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 17.6
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 1,030
  • P/B Ratio
  • 3.2
  • Average True Range
  • 61.45
  • EPS
  • 68.26
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -11.06
  • RSI
  • 46.66
  • MFI
  • 60.7

Latest Stock News Updates

Q4FY26 & FY26 Result Announced for 3B BlackBio Dx Ltd.

Agrochemicals company 3B BlackBio Dx announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue for Q4FY26 was Rs 3,543.41 lakh, a decrease of 29.62% QoQ from Rs 5,034.73 lakh in Q3FY26 but an increase of 57.52% YoY from Rs 2,249.51 lakh in Q4FY25. For the full year FY26, revenue stood at Rs 14,191.81 lakh compared to Rs 9,646.86 lakh in FY25. Total Income: For Q4FY26, total income was Rs 4,558.29 lakh, down 18.51% QoQ from Rs 5,593.40 lakh in Q3FY26 and up 66.13% YoY from Rs 2,743.82 lakh in Q4FY25. For the full year FY26, total income reached Rs 16,747.62 lakh compared to Rs 11,155.22 lakh in FY25. Net Profit (PAT): Consolidated profit after tax for Q4FY26 was Rs 980.48 lakh, down 56.31% QoQ from Rs 2,244.29 lakh in Q3FY26 and up 22.02% YoY from Rs 803.55 lakh in Q4FY25. For the full year FY26, PAT was Rs 5,992.98 lakh compared to Rs 4,769.11 lakh in FY25. Standalone Financial Highlights: Revenue from Operations: In Q4FY26, revenue was Rs 2,463.01 lakh, representing an increase of 1.04% QoQ from Rs 2,437.62 lakh in Q3FY26 and a 7.00% increase YoY from Rs 2,301.97 lakh in Q4FY25. For the full year FY26, revenue stood at Rs 9,727.50 lakh compared to Rs 9,052.97 lakh in FY25. Total Income: Total income for Q4FY26 was Rs 2,593.34 lakh, down 10.60% QoQ from Rs 2,900.76 lakh in Q3FY26 and down 7.14% YoY from Rs 2,792.75 lakh in Q4FY25. For the full year FY26, total income reached Rs 11,143.70 lakh compared to Rs 10,555.55 lakh in FY25. Net Profit (PAT): The standalone profit after tax for Q4FY26 was Rs 744.65 lakh, a decrease of 48.50% QoQ from Rs 1,446.02 lakh in Q3FY26 and a decrease of 19.45% YoY from Rs 924.39 lakh in Q4FY25. For the full year FY26, PAT was Rs 4,931.69 lakh compared to Rs 4,755.95 lakh in FY25. Business Highlights: Dividend: The Board of Directors has recommended a final dividend of 50% i.e., Rs 5.00 per equity share of Rs 10 each for the financial year ended March 31, 2026. Segment Performance (Consolidated): Diagnostic kits: This segment contributed the majority of the revenue, with Rs 3,205.42 lakh in Q4FY26 and Rs 13,111.81 lakh for the full year FY26. Segment profit before interest and tax for FY26 was Rs 7,706.56 lakh. Agrochemicals: This segment recorded a revenue of Rs 337.99 lakh in Q4FY26 and Rs 1,080.00 lakh for the full year FY26. Segment profit before interest and tax for FY26 was Rs 14.12 lakh. Strategic Acquisition: One-time expenses were paid to consultants for M&A; Advisory and Due Diligence fees during the acquisition of Coris Bioconcept SRL, Belgium. The total amount paid for this in the full year FY26 was Rs 174.08 lakh. Expansion Details: Other income of Rs 7.82 crore was recorded at Coris Bioconcept SRL due to R&D; project expenses being capitalized as per Belgium laws. New Auditor Appointment: M/s Ali Jain & Sharma, Chartered Accountants, Bhopal, were appointed as the Internal Auditor of the Company for the financial year 2026-27. Result PDF

Q3FY26 Quarterly Result Announced for 3B BlackBio Dx Ltd.

Agrochemicals company 3B BlackBio Dx announced Q3FY26 results Revenue from Operations stood at Rs 5,043.73 lakh in Q3FY26 compared to Rs 2,539.25 lakh in Q3FY25 Profit Before tax stood at Rs 2,683.98 lakh in Q3FY26 compared to Rs 1,779.61 lakh in Q3FY25 Profit After tax stood at Rs 2,244.29 lakh in Q3FY26 compared to Rs 1,349.52 lakh in Q3FY25 Earnings Per Share stood at Rs 26.19 in Q3FY26 compared to Rs 15.75 in Q3FY25 Result PDF

Q3FY25 Quarterly Result Announced for 3B BlackBio Dx Ltd.

Agrochemicals company 3B BlackBio Dx announced Q3FY25 results Revenue from Operations: Rs 2,539.25 lakh compared to Rs 1,766.89 lakh during Q3FY24. PBT: Rs 1,779.62 lakh compared to Rs 1,115.19 lakh during Q3FY24. PAT: Rs 1,349.53 lakh compared to Rs 851.68 lakh during Q3FY24. EPS: Rs 9.94 for Q3FY25. Result PDF

3B BlackBio Dx Financials

3B BlackBio Dx Technicals

EMA & SMA

Current Price
₹1,200.10
+ 1.5 (0.13%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,218.30
  • 50 Day
  • ₹1,246.70
  • 100 Day
  • ₹1,297.00
  • 200 Day
  • ₹1,362.00

Resistance and Support

1197.87 Pivot Speed
  • R3 1,265.73
  • R2 1,242.87
  • R1 1,220.73
  • S1 1,175.73
  • S2 1,152.87
  • S3 1,130.73

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

3b Blackbio Dx Ltd has an operating revenue of Rs. 141.92 Cr. on a trailing 12-month basis. An annual revenue growth of 50% is outstanding, Pre-tax margin of 54% is great, ROE of 18% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 128 indicates it belongs to a poor industry group of Chemicals-Agricultural and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

3B BlackBio Dx Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results & Final Dividend
2026-02-06 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results
2025-05-28 Audited Results & Dividend
Date Purpose Remarks
2025-09-19 FINAL Rs.4.00 per share(40%)Dividend
View 3B BlackBio Dx Dividend History Arrow

3B BlackBio Dx Shareholding Pattern

40.94%
0%
2.57%
37.73%
18.76%

3B BlackBio Dx FAQs

3B BlackBio Dx share price is ₹1,200 As on 22 June, 2026 | 13:15

The Market Cap of 3B BlackBio Dx is ₹1030 Cr As on 22 June, 2026 | 13:15

The P/E ratio of 3B BlackBio Dx is 17.6 As on 22 June, 2026 | 13:15

The PB ratio of 3B BlackBio Dx is 3.2 As on 22 June, 2026 | 13:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23